Level C· Early human research exploring benefitsCohort StudyEurope PMCOpen access

Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4 + T cells

Subramanian N., Hofwimmer K., Tavira B., Massier L., Andersson DP., Arner P.

Cohort Study with a reported sample of 17 on Type 2 Diabetes, published in Cardiovasc Diabetol (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Cardiovasc Diabetol (2023)
Reported sample size
17
Source database
Europe PMC
PMID
37046242
PMCID
PMC10099890
DOI
10.1186/s12933-023-01803-w
Citations
6

Abstract (original English)

Aim Obesity is linked to cardiometabolic diseases, however non-obese individuals are also at risk for type 2 diabetes (T2D) and cardiovascular disease (CVD). White adipose tissue (WAT) is known to play a role in both T2D and CVD, but the contribution of WAT inflammatory status especially in non-obese patients with cardiometabolic diseases is less understood. Therefore, we aimed to find associations between WAT inflammatory status and cardiometabolic diseases in non-obese individuals. Methods In a population-based cohort containing non-obese healthy (n = 17), T2D (n = 16), CVD (n = 18), T2D + CVD (n = 19) individuals, seventeen different cytokines were measured in WAT and in circulation. In addition, 13-color flow cytometry profiling was employed to phenotype the immune cells. Human T cell line (Jurkat T cells) was stimulated by rCCL18, and conditioned media (CM) was added to the in vitro cultures of human adipocytes. Lipolysis was measured by glycerol release. Blocking antibodies against IFN-γ and TGF-β were used in vitro to prove a role for these cytokines in CCL18-T-cell-adipocyte lipolysis regulation axis. Results In CVD, T2D and CVD + T2D groups, CCL18 and CD4 + T cells were upregulated significantly compared to healthy controls. WAT CCL18 secretion correlated with the amounts of WAT CD4 + T cells, which also highly expressed CCL18 receptors suggesting that WAT CD4 + T cell

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueT-LymphocytesCD4-Positive T-LymphocytesHumansCardiovascular DiseasesDiabetes Mellitus, Type 2ObesityGlycerolTransforming Growth Factor betaChemokines, CC

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research